Literature DB >> 2229068

Expression of human immunodeficiency virus 1 (HIV-1) envelope gene products transcribed from a heterologous promoter. Kinetics of HIV-1 envelope processing in transfected cells.

C Bird1, J Burke, P A Gleeson, J McCluskey.   

Abstract

The expression of human immunodeficiency virus 1 (HIV-1) envelope glycoprotein products was studied in cells transfected with env gene constructs transcribed from an SV40 promoter. Gene constructs possessing the complete tat, rev (tat+ rev+) and env genes were transiently expressed in COS-1 cells as precursor SU-TM (gp160), SU.TM (gp120 x 41), and nucleolar rev protein. In addition, envelope glycoprotein was detected on the surface of those transfected COS-1 cells expressing abundant levels of env protein. Transfected constructs possessing a mutated tat translational initiation codon (tat-rev+) were expressed in COS-1 cells with at least a 10-fold increase in the level of envelope glycoprotein expression compared to the analogous constructs with an intact tat AUG codon (tat+ rev+). Mutation of the rev initiation codon (tat+ rev-) and (tat-rev-) resulted in no detectable expression of env products but expression of these proteins could be rescued by co-transfection of a cDNA encoding the rev gene. Subgenomic tat/rev transcripts were detected following transfection of all of the gene constructs indicating splicing of the env mRNAs transcribed from a heterologous promoter. Unspliced env transcripts were only detected in the cytoplasm of cells transfected with (rev+) constructs or with the (tat- rev-) construct in the presence of the rev cDNA supplied in trans. In contrast, unspliced transcripts were detected in the nuclear and total cellular RNA of all transfected cells. Expression of rev protein was localized to the nucleolus of transfected COS-1 cells. These results indicate that the export of unspliced env mRNA to the cytoplasm is facilitated by the expression of rev. Following env synthesis, the conversion of SU-TM (gp160) to SU.TM (gp120 x 41) was not quantitative. After a 20-h pulse-chase, only 40% of the SU-TM (gp160) present at the start of the chase period was subsequently accountable as mature SU (gp120), and approximately 30% of the detectable SU (gp120) was found in the culture medium of transfected COS-1 cells. The findings indicate that the surface expression of SU.TM (gp120 x 41) derived from heterologous gene transcripts is modulated (i) the co-expression of rev, (ii) the efficiency of proteolytic processing of SU-TM (gp160), and (iii) the degree of SU (gp120) shedding and/or secretion from the cell.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229068

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.

Authors:  A Bültmann; W Muranyi; B Seed; J Haas
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Role of the HIV gp120 conserved domain 1 in processing and viral entry.

Authors:  Jizhen Wang; Jayita Sen; Lijun Rong; Michael Caffrey
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

Review 3.  Protein folding in the endoplasmic reticulum.

Authors:  Ineke Braakman; Daniel N Hebert
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

4.  Rate and severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS.

Authors:  D C Adamson; J C McArthur; T M Dawson; V L Dawson
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

5.  Mechanisms and structural determinants of HIV-1 coat protein, gp41-induced neurotoxicity.

Authors:  D C Adamson; K L Kopnisky; T M Dawson; V L Dawson
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

6.  The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function.

Authors:  Mark J Hollier; Nigel J Dimmock
Journal:  Virology       Date:  2005-07-05       Impact factor: 3.616

7.  Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART.

Authors:  Sharon A Riddler; Lu Zheng; Christine M Durand; Justin Ritz; Richard A Koup; Julie Ledgerwood; Robert T Bailer; Susan L Koletar; Joseph J Eron; Michael C Keefer; Bernard J C Macatangay; Joshua C Cyktor; John W Mellors
Journal:  Open Forum Infect Dis       Date:  2018-10-20       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.